Anne-Virginie Eggimann, Tessera Therapeutics chief regulatory officer
Bluebird’s regulatory chief departs two days after historic gene therapy nod to join Flagship’s Tessera
Just two days after securing FDA approval for the first gene therapy for a chronic condition, bluebird bio’s chief regulatory officer was on to her …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
